ArticleLeukemia2018
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
Abstract readValidation Study
In one paragraph
Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Targeting the p53/xCT/GSH Axis with PRIMA-1International journal of molecular sciences · 2025Article
- Antitumor Effects of PRIMA-1 and PRIMA-1Cells · 2021Review
- Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.Scientific reports · 2020Observational
- Heterogeneity ofFrontiers in oncology · 2020Review
- The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.British journal of cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Massimo GentileHematology Unit, Department of Onco-Hematology, A.O. of Cosenza, Cosenza, Italy. massim.gentile@tiscali.it.ORCID http://orcid.org/0000-0002-5256-0726
Tait D ShanafeltDepartment of Medicine, Division of Hematology, Stanford University, Stanford, CA, USA.
Gianluigi RedaHematology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy.
Francesca Romana MauroHematology, Department of Cellular Biotechnologies and Hematology, 'Sapienza' University, Rome, Italy.
Katja ZirlikDepartment of Haematology and Oncology, University Medical Centre Freiburg, Freiburg, Germany.
Stefania CiolliUniversity of Florence, Florence, Italy.
Luca LaurentiDepartment of Hematology, Catholic University Hospital "A. Gemelli", Rome, Italy.
Maria Ilaria Del PrincipeEmatologia, Dipartimento di Biomedicina e Prevenzione, Università degli studi di Roma "Tor Vergata", Rome, Italy.
Davide RossiOncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland.
Nicola Di RenzoUnità di Ematologia, Ospedale Vito Fazzi, Lecce, Italy.
Stefano MolicaDepartment of Oncology and Haematology, Pugliese-Ciaccio Hospital, Catanzaro, Italy.
Francesco AngrilliDepartment of Hematology, Ospedale Santo Spirito, Pescara, Italy.
Marta CosciaDivision of Haematology, University of Torino, A.O. Città della Salute e della Scienza di Torino, Torino, Italy.
Annalisa ChiarenzaDepartment of Biomedical Sciences, Division of Haematology, University of Catania and Ferrarotto Hospital, Catania, Italy.
Annamaria GiordanoEmatologia-Azienda Ospedaliero-Universitaria, Policlinico Consorziale di Bari, Bari, Italy.
Giovanna CutronaUO Molecular Pathology, Ospedale Policlinico San Martino IRCCS, Genova, Italy.ORCID http://orcid.org/0000-0002-3335-1101
Kari G ChaffeeDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-7313-1875
Sameer A ParikhDepartment of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Giuseppina UccelloHematology Unit, Department of Onco-Hematology, A.O. of Cosenza, Cosenza, Italy.
Idanna InnocentiDepartment of Hematology, Catholic University Hospital "A. Gemelli", Rome, Italy.
Giovanni TripepiConsiglio Nazionale delle Ricerche, Instituto di Biomedicina ed Immunologia Molecolare, Reggio Calabria, Italy.
Graziella D'ArrigoConsiglio Nazionale delle Ricerche, Instituto di Biomedicina ed Immunologia Molecolare, Reggio Calabria, Italy.
Ernesto VignaHematology Unit, Department of Onco-Hematology, A.O. of Cosenza, Cosenza, Italy.
Anna Grazia RecchiaBiotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, Aprigliano, Italy.
Yair HerishanuDepartment of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Lev ShvidelHematology Institute, Kaplan Medical Center, Rehovot, Israel.
Tamar TadmorHematology Unit, Bnai-Zion Medical Center, Haifa, Israel.
Agostino CortelezziHematology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy.
Giovanni Del PoetaEmatologia, Dipartimento di Biomedicina e Prevenzione, Università degli studi di Roma "Tor Vergata", Rome, Italy.
Gianluca GaidanoDivision of Haematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
Francesco Di RaimondoDepartment of Biomedical Sciences, Division of Haematology, University of Catania and Ferrarotto Hospital, Catania, Italy.
Antonino NeriHematology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy.
Manlio FerrariniDirezione Scientifica Ospedale Policlinico San Martino IRCCS, Genova, Italy.
Robin FoàHematology, Department of Cellular Biotechnologies and Hematology, 'Sapienza' University, Rome, Italy.
Aaron PolliackDepartment of Hematology, Hadassah University, Hospital and Hebrew University Medical School, Jerusalem, Israel.
Fortunato MorabitoConsiglio Nazionale delle Ricerche, Instituto di Biomedicina ed Immunologia Molecolare, Reggio Calabria, Italy.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Severity of Illness IndexAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBiomarkers, TumorCohort StudiesFemaleFollow-Up StudiesHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRituximabBendamustine HydrochlorideBiomarkers, TumorRituximab
Identifiers
PMID
29588545What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.